argenx SE (NASDAQ:ARGX) Shares Sold by Verition Fund Management LLC

Verition Fund Management LLC lowered its holdings in argenx SE (NASDAQ:ARGX) by 62.8% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,968 shares of the company’s stock after selling 10,062 shares during the period. Verition Fund Management LLC’s holdings in argenx were worth $3,235,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. J.Safra Asset Management Corp grew its holdings in argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after acquiring an additional 59 shares in the last quarter. Blue Trust Inc. grew its holdings in argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after acquiring an additional 62 shares in the last quarter. GAMMA Investing LLC grew its holdings in argenx by 51.3% during the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after acquiring an additional 40 shares in the last quarter. Cromwell Holdings LLC grew its holdings in argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares in the last quarter. Finally, Point72 Hong Kong Ltd acquired a new position in argenx during the 2nd quarter worth approximately $76,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analysts Set New Price Targets

ARGX has been the subject of several analyst reports. Wedbush reiterated an “outperform” rating and set a $655.00 price target on shares of argenx in a report on Tuesday. Oppenheimer restated an “outperform” rating and set a $675.00 price objective (up previously from $646.00) on shares of argenx in a research report on Thursday, November 21st. JMP Securities upped their price target on shares of argenx from $497.00 to $606.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Piper Sandler upped their price target on shares of argenx from $553.00 to $620.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Finally, Citigroup upped their price objective on shares of argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $635.42.

argenx Trading Up 3.0 %

Shares of NASDAQ ARGX opened at $624.96 on Thursday. The stock has a market cap of $37.73 billion, a price-to-earnings ratio of -710.18 and a beta of 0.59. argenx SE has a 52 week low of $327.73 and a 52 week high of $626.00. The company’s 50-day moving average price is $570.76 and its 200 day moving average price is $502.32.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The firm had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period in the prior year, the company earned ($1.25) EPS. As a group, research analysts expect that argenx SE will post 2.2 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.